Posted on 08/02/2010 in Pharmaceutical Company Product News Abbott announced this week that it has signed a contract with Pierre Fabre SA for the development of novel cancer treatments.
The focus of their joint efforts will be h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre in France which targets the cMet receptor for the treatment of cancer.
Under the terms of the agreement, the companies also plan to collaborate on research to explore next-generation cMet antibodies.
The cMet protein plays a role in the progression of a range of solid tumours including prostate, lung and gastric cancers and mediates resistance to chemotherapy.
John Leonard, senior vice-president of global research and development at Abbott, commented: "cMet is a compelling cancer target and the early research on this compound looks promising. We look forward to adding to our strong oncology pipeline, which includes exploration of multiple mechanisms to treat cancer."
In other Abbott news, the firm announced last week that its international pharmaceutical sales rose by 22.1 per cent last year.Other news stories from 08/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
